June 5, 2022

Lilly's AWARD-PEDS trial investigating use of Trulicity (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo

…82nd Scientific Sessions and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population… Source

Lilly's AWARD-PEDS trial investigating use of Trulicity (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo Read More »